Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

Gilead Sciences, Inc.Trade
Invesco NASDAQ 100 ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Invesco NASDAQ 100 ETF — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Invesco NASDAQ 100 ETF trades at $297.9. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDQQQM
Market Cap
$168.35B
Sector
HealthBroad Market / Factor
52-Week High
$155.80$307.23
52-Week Low
$110.56$229.87
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.

The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.

Invesco NASDAQ 100 ETF

QQQM trades at $297.98, up 0.4% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with lower fees than its QQQ counterpart, making it attractive for long-term investors. Recent news highlights its popularity among growth-focused investors and retirees seeking exposure to technology and innovation stocks.

The ETF's performance remains tied to the 'Magnificent Seven' tech stocks, with historical annual returns around 14%. While technical indicators show bullish momentum, the elevated RSI suggests potential near-term consolidation. Key risks include concentration in tech sector and market volatility affecting growth stocks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.

Read more on QQQM